Funded Grants

PI Name	PI Organization	Title	Grant Number Sort ascending	Program Official
Chung, Ki Young	Prisma Health - Upstate United States	NCORP of the Carolinas (Greenville Health System NCORP)	6UG1CA189972-10	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Chung, Ki Young	Prisma Health - Upstate United States	NCORP of the Carolinas (Greenville Health System NCORP)	6UG1CA189972-10	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Chung, Ki Young	Prisma Health - Upstate United States	NCORP of the Carolinas (Greenville Health System NCORP)	6UG1CA189972-10	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Chung, Ki Young	Prisma Health - Upstate United States	NCORP of the Carolinas (Greenville Health System NCORP)	6UG1CA189972-10	Brandy Heckman-Stoddard, Ph.D., M.P.H.
Wang, Jing	New York University School Of Medicine United States	Optimizing the use of ketamine to reduce chronic postsurgical pain	5UH3CA261067-04	Brennan Streck, Ph.D., R.N., M.P.H.
Largaespada, David Andrew	University Of Minnesota United States	Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention	5UH3CA244687-05	Mark Steven Miller, Ph.D.
Largaespada, David Andrew	University Of Minnesota United States	Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention	5UH3CA244687-05	Mark Steven Miller, Ph.D.
Largaespada, David Andrew	University Of Minnesota United States	Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention	5UH3CA244687-05	Mark Steven Miller, Ph.D.
Largaespada, David Andrew	University Of Minnesota United States	Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention	5UH3CA244687-05	Mark Steven Miller, Ph.D.
Frazier, Anne Lindsay	Dana-Farber Cancer Inst United States	Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors	5UH3CA240688-05